[CAPRICORN and COPERINUS studies].
The CAPRICORN and COPERNICUS studies have confirmed the significance of betablocker treatment with carvedilol for indications which this medication did not yet possess: post-infarction with left ventricular dysfunction with or without clinical signs, and stable severe cardiac insufficiency. The reduction in morbidity and mortality obtained thanks to this therapy places it in the treatment of cardiac insufficiency in association with the angiotensin converting enzyme inhibitors which remain unsurpassed.
Juillière
Y
Y
Département de cardiologie, CHU Nancy-Brabois, allée du Morvan, 54500 Vandoeuvre-les-Nancy.
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D002227:Carbazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000401:mortality; D000077261:Carvedilol; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000150:complications*; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000209:etiology
D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol
Etudes CAPRICORN et COPERNICUS.